康寧傑瑞製藥(09966.HK)JSKN003治療PROC初步呈現總生存期獲益趨勢
康寧傑瑞製藥(09966.HK)公布,JSKN003的最新研究成果已於5月30日至6月3日舉行的2025年ASCO年會壁報展示期間公布。
JSKN003-101為一項於澳洲晚期/轉移性實體瘤患者中開展的首次人體、開放性標籤和多中心的I期臨床研究,分為劑量遞增階段和劑量擴展階段。JSKN003-102為一項於中國晚期實體瘤患者中開展的I期(劑量遞增及劑量擴展)及II期(隊列擴展)臨床研究。
隨著隨訪時間延長,JSKN003治療鉑耐藥復發性上皮性卵巢癌(PROC)顯示出穩健的無進展生存期(PFS)獲益,並初步呈現總生存期(OS)獲益趨勢。JSKN003在經多線治療的人表皮生長因子受體2(HER2)陽性乳腺癌(BC)患者(包括既往接受過T-DXd治療的的患者)中展現良好的抗腫瘤活性及可控的安全性。JSKN003在經多線治療的HER2高表達(IHC3+)胃腸道腫瘤患者(包括既往接受過伊立替康治療的的患者)中展現出積極療效,且安全性可控可預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.